• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NOX
Click for more information
3.13% 6.6¢

NOXOPHARM LIMITED - News & Media

Market Cap $19.28M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Noxopharm Limited is an Australia-based biotechnology company. The Company is engaged in... Noxopharm Limited is an Australia-based biotechnology company. The Company is engaged in the discovery and development of treatments for cancer and inflammation. The Company has three active drug development programs: its clinical drug candidate Veyonda, plus two technology platforms, Chroma (oncology) and Sofra (inflammation and autoimmunity), which provide the basis for the active development of a growing pipeline of drugs. Veyonda (Idronoxil) is an adjuvant therapy in chemotherapy and radiotherapy in the treatment of late-stage cancers. The Chroma drug candidates have bioactive properties, which it is exploring primarily in the anti-cancer space. Its Sofra platform is centered around short nucleic acid sequences called oligonucleotides, which can act on specific cell receptors to stop inflammation, which is a source of various debilitating and lethal diseases. It is also conducting a dose escalation and dose expansion study of NOX66 in the treatment of COVID-19 infection.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Articles & Videos

Noxopharm (ASX:NOX) publishes preliminary data from phase one Veyonda trial

Aussie biotech company Noxopharm (NOX) has wrapped up its IONIC investigator-initiated pilot for its oncology drug Veyonda.

26 May 2023 15:19 (AEST)

Noxopharm (ASX:NOX) narrows focus on “cutting-edge” Chroma and Sofra programs

NSW-based biotech company Noxopharm (ASX:NOX) has announced its decision to prioritise the development of its two "cutting-edge" preclinical technology platforms moving forward – Chroma and Sofra.

06 Apr 2023 10:45 (AEST)

Noxopharm (ASX:NOX) announces novel mRNA "vaccine enhancer" product

Biotech company Noxopharm (ASX:NOX) has created an mRNA "vaccine enhancer" to improve the effectiveness of vaccines and reduce inflammation.

28 Mar 2023 12:26 (AEDT)

Noxopharm (ASX:NOX) receives green light to progress DARRT-2 trial

Noxopharm (ASX:NOX) is set to progress to part two of its clinical trial of its drug candidate Veyonda to treat prostate cancer.

17 Jan 2023 10:35 (AEDT)



(20min delay)
Last
6.6¢ 		Change
0.002(3.13%) 		Mkt cap ! $19.28M
Open High Low Value Volume
6.6¢ 6.6¢ 6.6¢ $1.313K 19.89K

Buyers (Bids)

No. Vol. Price($)
1 100000 6.7¢
 

Sellers (Offers)

Price($) Vol. No.
6.8¢ 14925 1
View Market Depth
Last trade - 11.32am 29/04/2024 (20 minute delay) ?
Last
6.6¢ 		  Change
0.002 ( 0.00 %)
Open High Low Volume
6.9¢ 6.9¢ 6.6¢ 47961
Last updated 11.00am 29/04/2024 ?
NOX (ASX) Chart

Top Stories

Recharged Prospects: 'Watts' on the horizon for copper & lithium

The conversation goes much deeper that this title suggests - it explores everything from projections on aluminium & manganese, to what a Donald Trump government could mean for commodities markets.
Regal copper grades at Gascoyne play see shares jump 33% for Augustus Augustus Minerals is reporting high grade copper rock chip results at Ti-Tree in WA based on recent fieldwork.
BHP confirms £31.1B takeover bid for Anglo American BHP HAS confirmed its offer to takeover fellow mining giant Anglo American plc, following press speculation of a potential deal.which had unsettled shareholder groups and financial firms in London, and provoked criticism from a South African government minister.
Are there gains to be made with the grocery giants? There is a growing storm of controversy around Coles (ASX:COL) and Woolworths (ASX:WOW) as they face intense scrutiny over price hikes and supplier pressures in a Senate inquiry. This raises an interesting question as to whether investors should cut ties with these corporate giants or wheth...
Carnarvon revs up for revised Dorado Development The Dorado discovery appears on again, with Carnarvon Energy announcing the JV completing a revision of the project’s design to optimise capital costs and accelerate FID by the end of 2024.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.